30
Participants
Start Date
April 30, 2023
Primary Completion Date
April 25, 2026
Study Completion Date
April 25, 2027
CD7 CAR-T cells injection
CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
Allogeneic hematopoietic stem cell transplantation
In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
RECRUITING
The first affiliated hospital of medical college of zhejiang university, Hangzhou
Yake Biotechnology Ltd.
INDUSTRY
Zhejiang University
OTHER